当前位置: 首页 >> 检索结果
4781. Long-Term Outcomes After Melody Transcatheter Pulmonary Valve Replacement in the US Investigational Device Exemption Trial.
作者: Thomas K Jones.;Doff B McElhinney.;Julie A Vincent.;William E Hellenbrand.;John P Cheatham.;Darren P Berman.;Evan M Zahn.;Danyal M Khan.;John F Rhodes.;Shicheng Weng.;Lisa J Bergersen.
来源: Circ Cardiovasc Interv. 2022年15卷1期e010852页
The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preserving RV function and reducing the lifetime burden of surgery for patients with complex congenital heart disease.
4784. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
作者: Perry Elliott.;Brian M Drachman.;Stephen S Gottlieb.;James E Hoffman.;Scott L Hummel.;Daniel J Lenihan.;Ben Ebede.;Balarama Gundapaneni.;Benjamin Li.;Marla B Sultan.;Sanjiv J Shah.
来源: Circ Heart Fail. 2022年15卷1期e008193页
Tafamidis is approved in many countries for the treatment of transthyretin amyloid cardiomyopathy. This study reports data on the long-term efficacy of tafamidis from an ongoing long-term extension (LTE) to the pivotal ATTR-ACT (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
4787. Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventricular Contractility.
作者: Sasha Z Prisco.;Lynn M Hartweck.;Lauren Rose.;Patricia D A Lima.;Thenappan Thenappan.;Stephen L Archer.;Kurt W Prins.
来源: Circ Heart Fail. 2022年15卷1期e008574页
Right ventricular dysfunction (RVD) is the leading cause of death in pulmonary arterial hypertension (PAH), but no RV-specific therapy exists. We showed microtubule-mediated junctophilin-2 dysregulation (MT-JPH2 pathway) causes t-tubule disruption and RVD in rodent PAH, but the druggable regulators of this critical pathway are unknown. GP130 (glycoprotein 130) activation induces cardiomyocyte microtubule remodeling in vitro; however, the effects of GP130 signaling on the MT-JPH2 pathway and RVD resulting from PAH are undefined.
4788. PRDM16 Is a Compact Myocardium-Enriched Transcription Factor Required to Maintain Compact Myocardial Cardiomyocyte Identity in Left Ventricle.
作者: Tongbin Wu.;Zhengyu Liang.;Zengming Zhang.;Canzhao Liu.;Lunfeng Zhang.;Yusu Gu.;Kirk L Peterson.;Sylvia M Evans.;Xiang-Dong Fu.;Ju Chen.
来源: Circulation. 2022年145卷8期586-602页
Left ventricular noncompaction cardiomyopathy (LVNC) was discovered half a century ago as a cardiomyopathy with excessive trabeculation and a thin ventricular wall. In the decades since, numerous studies have demonstrated that LVNC primarily has an effect on left ventricles (LVs) and is often associated with LV dilation and dysfunction. However, in part because of the lack of suitable mouse models that faithfully mirror the selective LV vulnerability in patients, mechanisms underlying the susceptibility of LVs to dilation and dysfunction in LVNC remain unknown. Genetic studies have revealed that deletions and mutations in PRDM16 (PR domain-containing 16) cause LVNC, but previous conditional Prdm16 knockout mouse models do not mirror the LVNC phenotype in patients, and the underlying molecular mechanisms by which PRDM16 deficiency causes LVNC are still unclear.
4789. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.
作者: Matthew A Cavender.;Robert A Harrington.;Gregg W Stone.;Ph Gabriel Steg.;C Michael Gibson.;Christian W Hamm.;Matthew J Price.;Renato D Lopes.;Sergio Leonardi.;Efthymios N Deliargyris.;Jayne Prats.;Kenneth W Mahaffey.;Harvey D White.;Deepak L Bhatt.; .
来源: Circ Cardiovasc Interv. 2022年15卷1期e010390页
Thrombotic events are reduced with cangrelor, an intravenous P2Y12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).
4790. Racial Disparities in Invasive Management for Patients With Acute Myocardial Infarction With Chronic Kidney Disease.
作者: Jennifer A Rymer.;Shuang Li.;Patrick H Pun.;Laine Thomas.;Tracy Y Wang.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011171页
Due to increased risks of contrast nephropathy, chronic kidney disease (CKD) can deter consideration of invasive management for patients with myocardial infarction (MI). Black patients have a higher prevalence of CKD. Whether racial disparities exist in the use of invasive MI management for patients with CKD presenting with MI is unknown.
4791. AtheroSpectrum Reveals Novel Macrophage Foam Cell Gene Signatures Associated With Atherosclerotic Cardiovascular Disease Risk.
作者: Chuan Li.;Lili Qu.;Alyssa J Matz.;Patrick A Murphy.;Yongmei Liu.;Ani W Manichaikul.;Derek Aguiar.;Stephen S Rich.;David M Herrington.;David Vu.;W Craig Johnson.;Jerome I Rotter.;Wendy S Post.;Anthony T Vella.;Annabelle Rodriguez-Oquendo.;Beiyan Zhou.
来源: Circulation. 2022年145卷3期206-218页
Whereas several interventions can effectively lower lipid levels in people at risk for atherosclerotic cardiovascular disease (ASCVD), cardiovascular event risks remain, suggesting an unmet medical need to identify factors contributing to cardiovascular event risk. Monocytes and macrophages play central roles in atherosclerosis, but studies have yet to provide a detailed view of macrophage populations involved in increased ASCVD risk.
4792. DREAM-ICD-II Study.
作者: Christian Steinberg.;Nicolas Dognin.;Amit Sodhi.;Catherine Champagne.;John A Staples.;Jean Champagne.;Zachary W Laksman.;Jean-François Sarrazin.;Matthew T Bennett.;Benoit Plourde.;Marc W Deyell.;Jason G Andrade.;Karine Roy.;John A Yeung-Lai-Wah.;Nathaniel M Hawkins.;Blandine Mondésert.;Louis Blier.;Isabelle Nault.;Gilles O'Hara.;Andrew D Krahn.;François Philippon.;Santabhanu Chakrabarti.
来源: Circulation. 2022年145卷10期742-753页
Regulatory authorities of most industrialized countries recommend 6 months of private driving restriction after implantation of a secondary prevention implantable cardioverter-defibrillator (ICD). These driving restrictions result in significant inconvenience and social implications. This study aimed to assess the incidence rate of appropriate device therapies in contemporary recipients of a secondary prevention ICD.
4793. Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review.
作者: Sunny Wei.;NhatChinh Le.;Jie Wei Zhu.;Khadijah Breathett.;Stephen J Greene.;Mamas A Mamas.;Faiez Zannad.;Harriette G C Van Spall.
来源: Circ Heart Fail. 2022年15卷3期e008685页
Heart failure has a disproportionate burden on patients who are Black, Indigenous, and people of color (BIPOC), but not much is known about representation of these groups in randomized controlled trials (RCTs). We explored temporal trends in and RCT factors associated with the reporting of race and ethnicity data and the enrollment of BIPOC in heart failure RCTs.
4794. Detection of Left Atrial Myopathy Using Artificial Intelligence-Enabled Electrocardiography.
作者: Frederik H Verbrugge.;Yogesh N V Reddy.;Zachi I Attia.;Paul A Friedman.;Peter A Noseworthy.;Francisco Lopez-Jimenez.;Suraj Kapa.;Barry A Borlaug.
来源: Circ Heart Fail. 2022年15卷1期e008176页
Left atrial (LA) myopathy is common in patients with heart failure and preserved ejection fraction and leads to the development of atrial fibrillation (AF). We investigated whether the likelihood of LA remodeling, LA dysfunction, altered hemodynamics, and risk for incident AF could be identified from a single 12-lead ECG using a novel artificial intelligence (AI)-enabled ECG analysis.
4795. Long-Term Outcomes in Adult Patients With Pulmonary Hypertension After Percutaneous Closure of Atrial Septal Defects.
作者: Selai Akseer.;Lusine Abrahamyan.;Douglas S Lee.;Ella Huszti.;Lukas M Meier.;Mark Osten.;Lee Benson.;Eric Horlick.
来源: Circ Cardiovasc Interv. 2022年15卷1期e011110页
Pulmonary hypertension (PH), recently redefined as mean pulmonary arterial pressure >20 mm Hg (PH20), may be observed in patients with atrial septal defects (ASD). We aimed to determine the effect of preprocedural PH20 status on outcomes among patients undergoing ASD closure.
4796. Exercise Training Protects Against Heart Failure Via Expansion of Myeloid-Derived Suppressor Cells Through Regulating IL-10/STAT3/S100A9 Pathway.
作者: Lifeng Feng.;Guangru Li.;Jiale An.;Chang Liu.;Xiaolong Zhu.;Yang Xu.;Yang Gao.;Jing Li.;Jie Liu.;Jie Yan.;Yachen Wang.;Jiling Ren.;Liang Yang.;Zhi Qi.
来源: Circ Heart Fail. 2022年15卷3期e008550页
Exercise training (ET) has a protective effect on the progression of heart failure, however, the specific mechanism has not been fully explored. Myeloid-derived suppressor cells (MDSCs) are a group of myeloid-derived immunosuppressive cells, which showed a protective effect in the progression of heart failure. Thus, we hypothesized that the protective effect of ET on heart failure may be related to the infiltration of MDSCs.
4797. Mechanisms of Sinoatrial Node Dysfunction in Heart Failure With Preserved Ejection Fraction.
作者: Thassio Mesquita.;Rui Zhang.;Jae Hyung Cho.;Rui Zhang.;Yen-Nien Lin.;Lizbeth Sanchez.;Joshua I Goldhaber.;Joseph K Yu.;Jialiu A Liang.;Weixin Liu.;Natalia A Trayanova.;Eugenio Cingolani.
来源: Circulation. 2022年145卷1期45-60页
The ability to increase heart rate during exercise and other stressors is a key homeostatic feature of the sinoatrial node (SAN). When the physiological heart rate response is blunted, chronotropic incompetence limits exercise capacity, a common problem in patients with heart failure with preserved ejection fraction (HFpEF). Despite its clinical relevance, the mechanisms of chronotropic incompetence remain unknown.
4798. Reading Frame Repair of TTN Truncation Variants Restores Titin Quantity and Functions.
作者: Robert Romano.;Shahnaz Ghahremani.;Talia Zimmerman.;Nicholas Legere.;Ketan Thakar.;Feria A Ladha.;Anthony M Pettinato.;J Travis Hinson.
来源: Circulation. 2022年145卷3期194-205页
Titin truncation variants (TTNtvs) are the most common inheritable risk factor for dilated cardiomyopathy (DCM), a disease with high morbidity and mortality. The pathogenicity of TTNtvs has been associated with structural localization as A-band variants overlapping myosin heavy chain-binding domains are more pathogenic than I-band variants by incompletely understood mechanisms. Demonstrating why A-band variants are highly pathogenic for DCM could reveal new insights into DCM pathogenesis, titin (TTN) functions, and therapeutic targets.
4799. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
作者: Ahmed M Shaman.;Stephen C Bain.;George L Bakris.;John B Buse.;Thomas Idorn.;Kenneth W Mahaffey.;Johannes F E Mann.;Michael A Nauck.;Søren Rasmussen.;Peter Rossing.;Benjamin Wolthers.;Bernard Zinman.;Vlado Perkovic.
来源: Circulation. 2022年145卷8期575-585页
We assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes.
4800. Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy.
作者: Rune Boas.;Nikolay Sappler.;Lukas von Stülpnagel.;Mathias Klemm.;Ulrik Dixen.;Jens Jakob Thune.;Steen Pehrson.;Lars Køber.;Jens C Nielsen.;Lars Videbæk.;Jens Haarbo.;Eva Korup.;Niels Eske Bruun.;Axel Brandes.;Hans Eiskjær.;Anna M Thøgersen.;Berit T Philbert.;Jesper Hastrup Svendsen.;Jacob Tfelt-Hansen.;Axel Bauer.;Konstantinos D Rizas.
来源: Circulation. 2022年145卷10期754-764页
Identification of patients with nonischemic cardiomyopathy who may benefit from prophylactic implantation of a cardioverter-defibrillator. We hypothesized that periodic repolarization dynamics (PRD), a marker of repolarization instability associated with sympathetic activity, could be used to identify patients who will benefit from prophylactic implantable cardioverter defibrillator (ICD) implantation.
|